Science Explorer Back to mapMap

Most cited papers from Minerva Neurosciences (United States)

What are the most cited papers from Minerva Neurosciences (United States)?

The most cited paper from Minerva Neurosciences (United States) is "Analysis of shared heritability in common disorders of the brain" (Verneri Anttila et al., 2018), with 2,056 citations. Next come "The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder" (87) and "The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia" (77).

Showing 40 of 40 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Analysis of shared heritability in common disorders of the brain Verneri Anttila et al. · Science Open access577 authors 21 Jun 2018 2,056
2 The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder Kasper Recourt, Peter de Boer, Rob G. J. A. Zuiker et al. · Translational Psychiatry Open access 3 Sep 2019 87
3 The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia Sander Brooks, Gabriël E. Jacobs, Peter de Boer et al. · Journal of Psychopharmacology 15 Jan 2019 77
4 Network Analysis Indicates That Avolition Is the Most Central Domain for the Successful Treatment of Negative Symptoms: Evidence From the Roluperidone Randomized Clinical Trial Gregory P. Strauss, Farnaz Zamani Esfahlani, Hiroki Sayama et al. · Schizophrenia Bulletin Open access 31 Dec 2019 76
5 Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Michael H Davidson, Jay B. Saoud, Corinne Staner et al. · Schizophrenia Bulletin Open access 27 Jan 2022 63
6 A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity Peter de Boer, Wayne Curtis Drevets, Hany Z. Rofael et al. · Journal of Psychopharmacology 31 May 2018 53
7 Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms Richard S.E. Keefe, Philip D. Harvey, Anzalee Khan et al. · The Journal of Clinical Psychiatry 14 May 2018 34
8 Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: Reduced emotional experience and reduced emotional expression Philip D. Harvey, Jay B. Saoud, R. Luthringer et al. · Schizophrenia Research 2 Sep 2019 31
9 The brief negative symptom scale (BNSS): Sensitivity to treatment effects Brian W Kirkpatrick, Jay B. Saoud, Gregory P. Strauss et al. · Schizophrenia Research 21 Dec 2017 30
10 Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis Spyridon Siafis et al. · The Lancet Psychiatry 30 Nov 2023 24
11 Remote Assessment of Negative Symptoms of Schizophrenia David Gordon Daniel, Alex S. Cohen, Dawn I. Velligan et al. · Schizophrenia Bulletin Open Open access 2023 20
12 Network intervention analysis indicates that roluperidone achieves its effect on negative symptoms of schizophrenia by targeting avolition Sydney H James, Anthony O. Ahmed, Philip D. Harvey et al. · European Neuropsychopharmacology 17 Jul 2024 19
13 Long-term effects of Roluperidone on negative symptoms of schizophrenia Jonathan Rabinowitz, Corinne Staner, Jay B. Saoud et al. · Schizophrenia Research Open access 16 Mar 2023 19
14 Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them Oliver Howes et al. · American Journal of Psychiatry Review 8 Oct 2025 13
15 Personal and social adjustment effects of roluperidone in patients with schizophrenia and negative symptoms: Results from an exploratory outcome of a randomized placebo-controlled trial Jonathan Rabinowitz, Stefan Badescu, Pavel Palamarchuk et al. · Schizophrenia Research 30 Jul 2019 13
16 Depression in Heart Failure: A Systematic Review. Waguih William Ishak, Gabriel Edwards, Nathalie Herrera et al. · PubMed Open access 2020 12
17 Issues and Perspectives in Designing Clinical Trials for Negative Symptoms in Schizophrenia: Consensus Statements Stephen R. Marder, Michael H Davidson, Silvia Zaragoza et al. · Schizophrenia Bulletin Open Open access 2020 12
18 Efficacy and Safety of Seltorexant in Insomnia Disorder Sofie Mesens, Andrew D. Krystal, Rama Melkote et al. · JAMA Psychiatry Open access 13 Aug 2025 11
19 Targeted Treatment of Schizophrenia Symptoms as They Manifest, or Continuous Treatment to Reduce the Risk of Psychosis Recurrence Michael Davidson, William T. Carpenter · Schizophrenia Bulletin Open access 29 Sep 2023 11
20 Prevalence of prominent and predominant negative symptoms across different criteria for negative symptom severity and minimal positive symptoms: A comparison of different criteria Philip D. Harvey, Michael Davidson, J. Saoud et al. · Schizophrenia Research Open access 26 Jul 2024 7
21 Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial Matin Mortazavi et al. · CNS Drugs Open access 11 Sep 2025 5
22 Who has poor insight, my patient suffering from schizophrenia or myself? Michael H Davidson, Ofer Agid · European Neuropsychopharmacology 12 Jan 2023 5
23 Roluperidone monotherapy, a treatment for negative symptoms in schizophrenia Michael H Davidson, Nadine Noël, Florent Schmitt et al. · The International Journal of Neuropsychopharmacology Open access 20 May 2025 4
24 Diversity in Naturally Acquired Immunity to Group B Streptococcus: A Comparative Study of Women From Bangladesh, Malawi, and the United Kingdom Shadia Khandaker, Shilpee Sharma, Tom Hall et al. · The Journal of Infectious Diseases Open access 7 Dec 2024 3
25 Clinically Meaningful Improvement in the treatment of Negative Symptoms of Schizophrenia: The Case of Roluperidone Jonathan Rabinowitz, Stefan Leucht, Michael H Davidson et al. · medRxiv PreprintOpen access 9 Sep 2026 0
26 Cognitive decline in psychotic disorders: A longitudinal matched case-control study Noaz Cohen, Nomi Werbeloff, Lucian Tatsa-Laur et al. · Schizophrenia Research Cognition Open access 22 Aug 2026 0
27 Moderate to severe negative symptoms predict low risk of symptoms worsening in schizophrenia patients in CATIE Helene Speyer, Jonathan Rabinowitz, Remy Luthringer et al. · Schizophrenia Research Open access 6 Jun 2026 0
28 Negative symptoms in schizophrenia: Methodological challenges and emerging solutions for outcome measurement Armida Mucci, Michael Davidson, Sílvia Zaragoza Domingo et al. · Neuroscience Applied Open access 2026 0
29 Methodologic Considerations on Developing Drugs for Negative Symptoms and Cognitive Impairment in Schizophrenia M. Davidson, J. Saoud, Rémy Luthringer · Comprehensive approach to psychiatry Book chapter 2025 0
30 Olanzapine added to roluperidone, in patients with schizophrenia and negative symptoms, a safety open-label trial Michael Davidson, R. Luthringer, Jay B. Saoud et al. · Neuroscience Applied Open access 2024 0
31 Exposure to antipsychotic medications and risk for hip fracture: a population-based cohort study Amir Krivoy, Dana Arnheim, A. Dotan et al. · Neuroscience Applied Open access 2024 0
32 Antipsychotic medications reduce the risk for prostate cancer in males with schizophrenia: a population-based, cohort study Amir Krivoy, Dana Arnheim, A. Dotan et al. · Neuroscience Applied Open access 2024 0
33 Prevalence of Prominent and Predominant Negative Symptoms Across Different Criteria for Negative Symptom Severity And Clinical Stability: A Comparison of Different Criteria Philip D. Harvey, Michael Davidson, Jay B. Saoud et al. · SSRN Electronic Journal PreprintOpen access 2024 0
34 Caractérisation de l’architecture du sommeil par Somno-Art Software à partir de différentes sources de signaux cardiaques et actimétriques Laurie Thiesse, Benjamin Bleux, Rene Gebel et al. · Médecine du Sommeil 28 Feb 2024 0
35 Détection automatique des périodes de siestes par Somno-Art Software comparé à la Polysomnographie Antoine Viola, Laurie Thiesse, René Gebel et al. · Médecine du Sommeil 28 Feb 2024 0
36 THE ROMA COMMUNITY OF ROME: HEIRS TO THE LEGACY OF A GHETTO SYSTEM Jon Calame · Journal of Research in Architecture & Planning Open access 30 Dec 2010 0
37 Effet de la Paroxetine sur le sommeil de patients dépressifs analysé avec Somno-Art et la polysomnographie Antoine Viola, Laurie Thiesse, Luc Staner et al. · Médecine du Sommeil Mar 2023 0
38 Variabilité interscoreurs entre 5 centres de sommeil comparé à une analyse cardio-actimétrique Antoine Viola, Laurie Thiesse, Luc Staner et al. · Médecine du Sommeil Mar 2023 0
39 Effectiveness of oral versus long-acting antipsychotic treatment early-phase schizophrenia patients: an open-label randomized trial Inge Winter, Michael Davidson, Wolfgang W. Fleischhacker et al. · European Psychiatry Open access Jun 2022 0
40 S.09.04 New pharmacological treatments for negative symptoms: pitfalls and future perspectives of clinical trials M. Davidson, J. Saoud, C. Staner et al. · European Neuropsychopharmacology Dec 2019 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.